Fineline Cube

Follow:
14486 Articles
Changchun GeneScience Secures NMPA Approval for GS3‑007a Dry Suspension & Green‑lights GenSci140 ADC Trials
CompanyDrug

Changchun GeneScience Secures NMPA Approval for GS3‑007a Dry Suspension & Green‑lights GenSci140 ADC Trials

BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance
CompanyDrug

BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance

Changchun GeneScience Secures FDA Approval for GenSci143 – Bispecific ADC Targeting B7‑H3 & PSMA in Advanced Solid Tumors
CompanyDrug

Changchun GeneScience Secures FDA Approval for GenSci143 – Bispecific ADC Targeting B7‑H3 & PSMA in Advanced Solid Tumors

Qyuns Therapeutics Receives NMPA Trial Approvals for QX027N – Long‑Acting Bispecific Antibody Targeting Asthma and Atopic Dermatitis
CompanyDrug

Qyuns Therapeutics Receives NMPA Trial Approvals for QX027N – Long‑Acting Bispecific Antibody Targeting Asthma and Atopic Dermatitis

Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) – First‑In‑Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma
CompanyDrug

Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) – First‑In‑Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers
CompanyDeals

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened
CompanyDrug

Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened

Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes
CompanyDrug

Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes

Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact
CompanyDeals

Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial
CompanyDrug

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss
CompanyDrug

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart
CompanyDrug

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart